As of June 06, 2019, TODOS Authorized shares were 990mil and outstanding shares stood at 96.3mil. After the 1for25 RS, the AS will be 39.6mil and OS around 3.9 mil (excluding warrants). Although the stock price will be around $6, the final price will be determined by the discounted premium given to raise the $6m. It might take anywhere from 1m to 3m shares to accomplish this. In other words, after the capital raise, TODOS outstanding shares could be north of 10 mil fully diluted. The upshot is, the capital raise will give TODOS the resources to develop its assets including LymPro. Not too bad for an asset that was languishing in a limbo.

It might be tempting to buy some shares now; however, I personally would wait until after NASDAQ listing and capital raise.